Dietary phosphate and kidney health
All phosphate additives, including magnesium phosphates, contribute to total dietary phosphate intake. For people with chronic kidney disease (CKD), the kidneys cannot excrete excess phosphate efficiently, which can raise blood phosphate levels and contribute to bone and cardiovascular complications. Phosphate from food additives is absorbed more readily than from natural food sources. Clinical guidance for CKD patients routinely includes limiting phosphate additive intake.
Inorganic phosphate from food additives is absorbed at approximately 80-100% efficiency, compared with roughly 40-60% from naturally occurring organic phosphate in meat and grains, making additive sources a disproportionate contributor to phosphate load in people with impaired kidney function.
2015Regulatory reviewEFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Scientific Opinion on Dietary Reference Values for phosphorus
Elevated serum phosphate is independently associated with increased cardiovascular mortality in patients with chronic kidney disease.
2004ObservationalBlock et al., Journal of the American Society of Nephrology
Magnesium as a nutrient
Magnesium phosphates also deliver magnesium, an essential mineral involved in nerve function, muscle contraction, and bone formation. The magnesium component is bioavailable and can contribute positively to dietary magnesium intake at the levels typically found in food. The UK SACN has set dietary reference values for magnesium but has not flagged food-additive sources as a concern at current exposure levels.
EFSA set an Adequate Intake for magnesium of 300mg per day for adult women and 350mg for adult men, with food-additive sources contributing only a small fraction of typical daily intake.
2015Regulatory reviewEFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Scientific Opinion on Dietary Reference Values for magnesium
EFSA re-evaluation
EFSA conducted a systematic re-evaluation of phosphate additives (E338-341, E343, E450-452) as part of its programme to reassess all food additives authorised before 2009. The panel noted that combined exposure to phosphate additives across the whole group should be considered, particularly given high background dietary phosphate intake in modern diets. EFSA did not set a numerical ADI for the phosphate group as a whole, but noted that the no-observed-adverse-effect level from animal studies gave a margin of exposure considered adequate for the general population at current permitted use levels.
EFSA's re-evaluation of phosphate food additives (E338-343, E450-452) found no safety concern at current authorised uses and levels for the general population, but flagged that people with kidney disease represent a vulnerable group who may benefit from limiting all phosphate additive intake.
2019Regulatory reviewEFSA ANS Panel, Re-evaluation of phosphoric acid and phosphates (E338-341, E343, E450-452) as food additives